Abstract
Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.
J H Kehne, B M Baron, A A Carr, S F Chaney, J Elands, D J Feldman, R A Frank, P L van Giersbergen, T C McCloskey, M P Johnson, D R McCarty, M Poirot, Y Senyah, B W Siegel and C Widmaier
Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 968-981;
J H Kehne
B M Baron
A A Carr
S F Chaney
J Elands
D J Feldman
R A Frank
P L van Giersbergen
T C McCloskey
M P Johnson
D R McCarty
M Poirot
Y Senyah
B W Siegel
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Abstract
Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.
J H Kehne, B M Baron, A A Carr, S F Chaney, J Elands, D J Feldman, R A Frank, P L van Giersbergen, T C McCloskey, M P Johnson, D R McCarty, M Poirot, Y Senyah, B W Siegel and C Widmaier
Journal of Pharmacology and Experimental Therapeutics May 1, 1996, 277 (2) 968-981;
Abstract
Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.
J H Kehne, B M Baron, A A Carr, S F Chaney, J Elands, D J Feldman, R A Frank, P L van Giersbergen, T C McCloskey, M P Johnson, D R McCarty, M Poirot, Y Senyah, B W Siegel and C Widmaier
Journal of Pharmacology and Experimental Therapeutics May 1, 1996, 277 (2) 968-981;
Jump to section
Related Articles
Cited By...
Similar Articles
Advertisement